Phase 2 Study of Pevonedistat (P) Plus Azacitidine (A) Versus Azacitidine in Patients (pts) with Higher-Risk Myelodysplastic Syndromes (mds)/chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (LB-AML) (NCT02610777)
ONCOLOGY RESEARCH AND TREATMENT(2020)
Key words
pevonedistat,azacitidine,myelodysplastic syndromes,MDS,chronic myelomonocytic leukemia,acute myeloid leukemia,AML
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined